Sign In
Buy CTSO
$0.489
+0.0090 (+1.88%)
At Close: Jun 03, 2026
Cytosorbents Corporation (CTSO) Q1 2026 Earnings Call Transcript
07:30pm, Wednesday, 13'th May 2026
Cytosorbents Corporation (CTSO) Q1 2026 Earnings Call Transcript
CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
04:00pm, Wednesday, 13'th May 2026
PRINCETON, N.J., May 13, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blo
CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights
07:00am, Thursday, 30'th Apr 2026
PRINCETON, N.J., April 30, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b
Cytosorbents Corporation (CTSO) Q4 2025 Earnings Call Transcript
06:45pm, Wednesday, 25'th Mar 2026
Cytosorbents Corporation (CTSO) Q4 2025 Earnings Call Transcript
CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
04:05pm, Wednesday, 25'th Mar 2026
2025 revenue of $37.1 million, up 4% year-over-year, and 71% Full-year gross margins Enhanced Balance Sheet Flexibility with an Additional $2.5 million Proceeds from Amended Credit Facility in Novembe
CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026
09:44am, Thursday, 19'th Mar 2026
PRINCETON, N.J., March 19, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b
CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
07:00am, Thursday, 05'th Mar 2026
PRINCETON, N.J., March 5, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using bl
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update
07:00am, Monday, 12'th Jan 2026
Fourth quarter and Full-Year 2025 revenue are expected to be approximately $9.2 million and $37.0 million, respectively, with expected Q4 gross margins in the range of 73% to 75% DrugSorb®-ATR De No
Cytosorbents Corporation (CTSO) Discusses Progress in Blood-Purification Programs and DrugSorb-ATR's Regulatory Path Transcript
03:59pm, Monday, 15'th Dec 2025
Cytosorbents Corporation (CTSO) Discusses Progress in Blood-Purification Programs and DrugSorb-ATR's Regulatory Path Transcript
CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025
07:00am, Wednesday, 10'th Dec 2025
PRINCETON, N.J. , Dec. 10, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b
Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London
05:42pm, Monday, 17'th Nov 2025
PRINCETON, N.J. , Nov. 17, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using
Cytosorbents Corporation (CTSO) Q3 2025 Earnings Call Transcript
07:21pm, Thursday, 13'th Nov 2025
Cytosorbents Corporation ( CTSO ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Phillip Chan - CEO & Director Peter Mariani - Chief Financial Officer Conference Call Partici
CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update
04:05pm, Thursday, 13'th Nov 2025
Third quarter 2025 revenue of $9.5 million, up 10% year-over-year Amended credit agreement with Avenue Capital Group which strengthens our balance sheet with an additional $2.5 million of cash, and ex
CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London
07:00am, Tuesday, 11'th Nov 2025
PRINCETON, N.J. , Nov. 11, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b
CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights
07:00am, Thursday, 30'th Oct 2025
PRINCETON, N.J. , Oct. 30, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b
